Trial of Tykerb for HER2-Positive Breast Cancer Brain Mets Begins

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 15 No 1
Volume 15
Issue 1

SAN ANTONIO—GlaxoSmithKline has announced the initiation of a global multicenter phase II trial (known as EGF 105084) to evaluate Tykerb (lapatinib) for the treatment of ErbB2 (HER2)-overexpressing breast cancer that has metastasized to the brain. Tykerb is an orally bioavailable small molecule that potently inhibits two receptors, ErbB2 and ErbB1. It is currently in development as a first-line treatment for ErbB2-overexpressing breast cancer.

SAN ANTONIO—GlaxoSmithKline has announced the initiation of a global multicenter phase II trial (known as EGF 105084) to evaluate Tykerb (lapatinib) for the treatment of ErbB2 (HER2)-overexpressing breast cancer that has metastasized to the brain. Tykerb is an orally bioavailable small molecule that potently inhibits two receptors, ErbB2 and ErbB1. It is currently in development as a first-line treatment for ErbB2-overexpressing breast cancer.

Articles in this issue
FDA Approves Nexavar for Use in Advanced Kidney Cancer
Avastin Benefits Metastatic Breast Cancer
Amgen to Acquire Abgenix
Better Prognosis for ‘Elsewhere' Local Breast Ca Recurrences
Herceptin/Taxotere Ups DFS in Early HER2+ Breast Ca
NIH 2006 Budget Is Likely to Be Lower Than in 2005
Amooranin, a Plant Compound, Shows Potential as Cancer Treatment
Mesenchymal Stem Cell Transplantation Potential Novel Treatment for Patients With Severe Graft-vs-Host-Disease
FDA Launches 7 Initiatives With European Drug Regulators
Taxanes Comparable as Adjuvant Therapy of Breast Cancer; Weekly Paclitaxel More Effective Than q3wk
Lessons From Ongoing Clinical Experience With MammoSite Breast Brachytherapy
Antibody Detects AML-Associated Stem Cells
Trial of Tykerb for HER2-Positive Breast Cancer Brain Mets Begins
Len/Dex for Relapsed or Refractory Myeloma
Encouraging Results With Ixabepilone in Metastatic Breast Ca
Related Videos
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Carey Anders, MD, an expert on breast cancer
Carey Anders, MD, an expert on breast cancer
Carey Anders, MD, an expert on breast cancer
Carey K. Anders, MD, an expert on breast cancer
A panel of 4 experts on breast cancer seated at a long table
A panel of 4 experts on breast cancer seated at a long table
Related Content
The latest KEYNOTE-756 data highlight the surgical outcomes of patients with high-risk early-stage estrogen receptor–positive breast cancer.

Neoadjuvant/Adjuvant Pembrolizumab Regimens Lower RCB in ER+ Breast Cancer

April 19th 2024
Article

The latest KEYNOTE-756 data highlight the surgical outcomes of patients with high-risk early-stage estrogen receptor–positive breast cancer.

Sarah Donahue, MPH, NP, speaks to the importance of communicating potential adverse effects associated with treatments such as CDK4/6 inhibitors to patients with breast cancer.

Managing CDK4/6 Inhibitor, ADC Toxicity in Metastatic Breast Cancer

January 15th 2024
Podcast

Sarah Donahue, MPH, NP, speaks to the importance of communicating potential adverse effects associated with treatments such as CDK4/6 inhibitors to patients with breast cancer.

Results from the INSITE trial support the utility of pegulicianine fluorescence-guided surgery during breast cancer surgery.

FDA Approves Pegulicianine-Based Imaging for Breast Cancer Surgery

April 18th 2024
Article

Results from the INSITE trial support the utility of pegulicianine fluorescence-guided surgery during breast cancer surgery.

HER2CLIMB-02 Trial Shows ‘Interesting Data’ in HER2+ Breast Cancer

HER2CLIMB-02 Trial Shows ‘Interesting Data’ in HER2+ Breast Cancer

January 8th 2024
Podcast

Tucatinib plus trastuzumab emtansine shows a progression-free survival improvement in HER2-positive breast cancer in the phase 3 HER2CLIMB-02 trial, says Sara A. Hurvitz, MD, FACP.

An increased TIL count in the breast tissue was associated with improved distant recurrence-free survival in patients with triple-negative breast cancer.

Survival Outcomes Improve With TIL Presence in TNBC

April 16th 2024
Article

An increased TIL count in the breast tissue was associated with improved distant recurrence-free survival in patients with triple-negative breast cancer.

Updates in Breast Cancer Care From the 41st Annual Miami Breast Cancer Conference

Updates in Breast Cancer Care From the 41st Annual Miami Breast Cancer Conference

April 15th 2024
Article

Several presentations from the 41st Annual Miami Breast Cancer Conference focused on new and evolving data in the space, according to Neil M. Iyengar, MD.